×
About 910 results

ALLMedicine™ Pure Red Cell Aplasia Center

Research & Reviews  451 results

Atezolizumab-induced pure red cell aplasia.
https://doi.org/10.1111/bjh.17259
British Journal of Haematology; Bennett R, Ruskova A

Feb 14th, 2021 - Atezolizumab-induced pure red cell aplasia.|2021|Bennett R,Ruskova A,|

Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical b...
https://doi.org/10.1111/trf.16281
Transfusion Yates B, Molloy E et. al.

Feb 2nd, 2021 - Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratu...

Acquired pure red cell aplasia and T cell large granular lymphocytic leukaemia in patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814426
BMC Medical Genomics; Ruan J, Wang X et. al.

Jan 20th, 2021 - Pure red cell aplasia (PRCA) and large granular lymphocytic leukaemia (LGLL) are very rare complications of autoimmune polyendocrine syndrome type 1 (APS1). Here, we report a case of APS1 with PRCA and LGLL. Previous cases were reviewed, and possi...

Postnatal IVIG treatment for persistent anaemia in neonate due to congenital parvovirus...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802649
BMJ Case Reports; Janssen O, Lin J

Jan 12th, 2021 - Congenital parvovirus B19 infection is a rare but serious condition that can result in hydrops fetalis and fetal death. Due to the virus' cytotoxic effect on fetal red blood cell precursors, postnatal infection can cause a neonatal viremia and sec...

see more →

Clinicaltrials.gov  455 results

Atezolizumab-induced pure red cell aplasia.
https://doi.org/10.1111/bjh.17259
British Journal of Haematology; Bennett R, Ruskova A

Feb 14th, 2021 - Atezolizumab-induced pure red cell aplasia.|2021|Bennett R,Ruskova A,|

Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical b...
https://doi.org/10.1111/trf.16281
Transfusion Yates B, Molloy E et. al.

Feb 2nd, 2021 - Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratu...

Acquired pure red cell aplasia and T cell large granular lymphocytic leukaemia in patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814426
BMC Medical Genomics; Ruan J, Wang X et. al.

Jan 20th, 2021 - Pure red cell aplasia (PRCA) and large granular lymphocytic leukaemia (LGLL) are very rare complications of autoimmune polyendocrine syndrome type 1 (APS1). Here, we report a case of APS1 with PRCA and LGLL. Previous cases were reviewed, and possi...

Postnatal IVIG treatment for persistent anaemia in neonate due to congenital parvovirus...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802649
BMJ Case Reports; Janssen O, Lin J

Jan 12th, 2021 - Congenital parvovirus B19 infection is a rare but serious condition that can result in hydrops fetalis and fetal death. Due to the virus' cytotoxic effect on fetal red blood cell precursors, postnatal infection can cause a neonatal viremia and sec...

see more →

News  4 results

Brentuximab Vedotin in a Patient With Aggressive Systemic Mastocytosis and Pure Red Cell Aplasia
https://www.mdedge.com/fedprac/article/102811/lymphoma-plasma-cell-disorders/brentuximab-vedotin-patient-aggressive
Cooper K, Richter J et. al.

Sep 21st, 2015 - Backround: Mastocytosis is a rare disease with a variable clinical course. Pure red cell aplasia has not been frequently reported in association with aggressive systemic mastocytosis.

FDA Safety Changes: Actonel, Gardasil, Myfortic
https://www.medscape.com/viewarticle/708284

Sep 1st, 2009 - This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. September 2, 2009 — The US Food and Drug Administration (...

FDA Safety Changes: Strattera, Aptivus, CellCept
https://www.medscape.com/viewarticle/707021

Aug 4th, 2009 - This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. August 5, 2009 — The US Food and Drug Administration (FDA...

see more →